1 completed, 1 unknown, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow CT-322: new trials by email Literature Review of CT-322 trials Research Report on CT-322
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Japanese Phase 1 Study of BMS-844203 (CT322) BMS-844203 (CT-322) - Neoplasms | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2013-11-01 | 2012-02-07 | |
| CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme CT-322, Temozolomide, Radiation Therapy - Glioblastoma Multiforme | Phase 1 | Unknown | Adnexus, A Bristol-Myers Squibb R&D Company | 30 | 2008-10-01 | 2010-10-27 |
| CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma CT-322 - Cancer | Phase 1 | Completed | Adnexus, A Bristol-Myers Squibb R&D Company | 40 | 2006-08-01 | 2009-02-24 |
Neoplasms (2) · Glioblastoma (1)
Adnexus, A Bristol-Myers Squibb R&D Company (2) · Bristol-Myers Squibb (1)
United States (2) · Japan (1)